Skip to main content

Research Repository

Advanced Search

T‐cell responses and therapies against SARS‐CoV‐2 infection

Toor, SM; Saleh, R; Sasidharan Nair, V; Taha, RZ; Elkord, E

T‐cell responses and therapies against SARS‐CoV‐2 infection Thumbnail


Authors

SM Toor

R Saleh

V Sasidharan Nair

RZ Taha

E Elkord



Abstract

Coronavirus disease 2019 (COVID‐19) is caused by SARS‐CoV‐2, a novel coronavirus strain. Some studies suggest that COVID‐19 could be an immune‐related disease, and failure of effective immune responses in initial stages of viral infection could contribute to systemic inflammation and tissue damage, leading to worse disease outcomes. T cells can act as a double‐edge sword with both pro‐ and anti‐roles in the progression of COVID‐19. Thus, better understanding of their roles in immune responses to SARS‐CoV‐2 infection is crucial. T cells primarily react to the spike protein on the coronavirus to initiate antiviral immunity; however, T‐cell responses can be suboptimal, impaired or excessive in severe COVID‐19 patients. This review focuses on the multifaceted roles of T cells in COVID‐19 pathogenesis and rationalizes their significance in eliciting appropriate antiviral immune responses in COVID‐19 patients and unexposed individuals. In addition, we summarize the potential therapeutic approaches related to T cells to treat COVID‐19 patients. These include adoptive T‐cell therapies, vaccines activating T‐cell responses, recombinant cytokines, Th1 activators and Th17 blockers, and potential utilization of immune checkpoint inhibitors alone or in combination with anti‐inflammatory drugs to improve antiviral T‐cell responses against SARS‐CoV‐2.

Citation

Toor, S., Saleh, R., Sasidharan Nair, V., Taha, R., & Elkord, E. (2021). T‐cell responses and therapies against SARS‐CoV‐2 infection. Immunology, 162(1), 30-43. https://doi.org/10.1111/imm.13262

Journal Article Type Article
Acceptance Date Sep 4, 2020
Online Publication Date Sep 15, 2020
Publication Date Jan 1, 2021
Deposit Date Nov 12, 2020
Publicly Available Date Nov 12, 2020
Journal Immunology
Print ISSN 0019-2805
Electronic ISSN 1365-2567
Publisher Wiley
Volume 162
Issue 1
Pages 30-43
DOI https://doi.org/10.1111/imm.13262
Publisher URL https://doi.org/10.1111/imm.13262
Related Public URLs http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2567
Additional Information Additional Information : ** Article version: VoR ** From Crossref journal articles via Jisc Publications Router ** Licence for VoR version of this article starting on 27-10-2020: http://creativecommons.org/licenses/by/4.0/ **Journal IDs: pissn 0019-2805; eissn 1365-2567 **History: issued 27-10-2020; published_online 27-10-2020

Files







Downloadable Citations